• Vitex agnus-castus (Авраама дерево / Вітекс священний) в полегшенні симптомів менопаузи

Vitex agnus-castus (Авраама дерево / Вітекс священний) в полегшенні симптомів менопаузи

HEALTH OF WOMAN. 2018.9(135):26–35

Маргарет Діана ван Ді, доктор філософіі, Генрі Г. Бургер, лікар, член Королівської австралійської колегії лікарів загальної практики, Хелена Дж. Тееде, бакалавр медицини і бакалавр хірургії, доктор філософії, член Королівської австралійської колегії лікарів загальної практики і Керрі М. Боун, бакалавр наук, дипломований фітотерапевт, науковий співробітник Національного інституту психічного здоров'я, член Національної асоціації фітотерапевтів Австраліі

Мельбурнський королівський технологічний університет (RMIT), Бандоора, Вікторія, Австралія.
Інститут медичних досліджень принца Генрі, Клейтон, Вікторія, Австралія

Фонд Джин Хейлс, Інститут охорони здоров'я при університеті Монаша, Університет Монаша, Клейтон, Вікторія, Австралія
«МедіХерб», Уорік, Квінсленд, Австралія
Університет Нової Англії, Армідейл, Новий Південний Уельс, Клейтон, Вікторія, Австралія

Опубліковано: ЖУРНАЛ АЛЬТЕРНАТИВНОЇ ТА КОМПЛЕМЕНТАРНОЇ МЕДИЦИНИ. Том 15, Номер 8, 2009 стор. 835-862

© «Мері Енн Ліберт, Інк.»

DOI: 10.1089 / acm.2008.0447

СПИСОК ЛІТЕРАТУРИ

1. Mills S, Bone K. Principles and Practice of Phytotherapy. London: Churchill Livingstone, 2000.

2. Pizzorno J, Murray M. Textbook of Natural Medicine. New York: Churchill Livingstone, 2000.

3. Hawley R, Levick B, eds. Women in Antiquity: New Assessments. London, New York: Routledge, 1995.

4. Hobbs C. Vitex: The Women’s Herb. 2nd ed. Santa Cruz, CA: Botanica Press, 1990.

5. Attelmann H, Bends K, Hellenkemper H, Warkalla H. Agnolyt_ in the treatment of gynecological complaints [in German]. Z Pra¨ klin Geriatr 1972;2:239–243.

6. Fugh-Berman A. Herbs, phytoestrogens, and other CAM therapies. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:683.

7. Bone K. A Clinical Guide to Blending Liquid Herbs. St. Louis: Churchill Livingstone, 2003.

8. Mills S. The Dictionary of Modern Herbalism. Wellingborough, UK: Thorsons, 1985.

9. Newall C, Anderson L, Phillipson J. Herbal Medicines: A Guide for Health-care Professionals. London: The Pharmaceutical Press, 1996.

10. Christie S, Walker AF. Vitex agnus-castus L.: (1) A Review of Its Traditional and Modern Therapeutic use; (2) Current Use from a Survey of Practitioners. Eur J Herbal Med 1997;3:29–45.

11. Rotem C, Kaplan B. Phyto-female complex for the relief of hot flushes, night sweats and quality of sleep: Randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007;23:117–122.

12. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: A randomized trial. Ann Intern Med 2006;145:869–879.

13. van Die MD, Burger HG, Bone KM, et al. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms.

Menopause 2009;16:156–163.

14. Smolinski D, Wollner D, Orlowski J, et al. A pilot study to examine a combination botanical for the treatment of menopausal symptoms. J Altern Complement Med 2005; 11:483–489.

15. Wuttke W, Gorkow C, Jarry H. Dopaminergic compounds in Vitex agnus-castus. In: Leow D, Rietbrock, N, ed. Herbal Medicine in Research and Clinical Application [in German]. Darmstadt, Germany: Steinkopff (Verlag), 1995:81–91.

16. Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus): Pharmacology and clinical indications. Phytomedicine 2003;10:348–357.

17. Wuttke W. The use of chasteberry (Vitex agnus castus) extract in gynecology. Gynakol Endokrinol 2008;6:82–86.

18. Meier B, Berger D, Hoberg E, et al. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000;7:373–381.

19. Webster DE, Lu J, Chen SN, et al. Activation of the muopiate receptor by Vitex agnus-castus methanol extracts: Implication for its use in PMS. J Ethnopharmacol 2006;106: 216–221.

20. Dericks-Tan JS, Schwinn P, Hildt C. Dose-dependent stimulation of melatonin secretion after administration of Agnus castus: Experimental and clinical endocrinology & diabetes 2003;111:44–46.

21. Chopin Lucks B. Vitex agnus castus essential oil and menopausal balance: A research update. Complement Ther Nurs Midwifery 2003;9:157–160.

22. World Health Organisation. Research on the Menopause in the 1990s. Report of a WHO Scientific Group. WHO VITEX AGNUS-CASTUS IN MENOPAUSE 859 Technical Report Series No. 866. Geneva: WHO Library Cataloguing in Publication Data, 1996.

23. Lucks BC, Sørensen J, Veal L. Vitex agnus-castus essential oil and menopausal balance: A self-care survey. Complement Ther Nurs Midwifery 2002;8:148–154.

24. Mitchell E, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women’s Health Study: Toward a more precise definition. Menopause 2000;7:334–349.

25. Burger H. The endocrinology of the menopause. J Steroid Biochem Molecular Biol 1999;69:31–35.

26. Burger H. The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause 2005;12:276–274.

27. Santoro N, Brown JR, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab 1996;81:1495–1501.

28. Dennerstein L, Smith AM, Morse C, et al. Menopausal symptoms in Australian women. Med J Aust 1993;159:232– 236.

29. Van Look PF, Lothian H, Hunter WM, et al. Hypothalamicpituitary- ovarian function in perimenopausal women. Clin Endocrinol (Oxf ) 1977;7:13–31.

30. Teede H, Buger H. The menopausal transition. In: Studd JW, ed. The Management of the Menopause. Annual Review. New York: Elsevier, 1998:1–18.

31. Guthrie JR, Dennerstein L, Taffe JR, et al. Hot flushes during the menopause transition: A longitudinal study in Australian-born women. Menopause 2005;12:460–467.

32. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351–358.

33. Nilsson K, Heimer G. Endogenous estrogen levels in postmenopausal women with severe urogenital atrophy. Gynecol Obstet Invest 1992;34:234–236.

34. Burger H, Dudley E, Robertson D, Dennerstein L. Hormonal changes in the menopause transition. Recent Prog Hormone Res 2002;57:257–275.

35. Fraser IS, Baird DT. Blood production and ovarian secretion rates of estradiol-17 beta and estrone in women with dysfunctional uterine bleeding. J Clin Endocrinol Metab 1974;39:564–570.

36. Bungay GT, Vessey MP, McPherson CK. Study of symptoms in middle life with special reference to the menopause. Br Med J 1980;281:181–183.

37. Freeman EW, Sammel MD, Liu L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62–70.

38. Robinson GE. Psychotic and mood disorders associated with the perimenopausal period: Epidemiology, aetiology and management. CNS Drugs 2001;15:175–184.

39. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: A multiethnic community study. Am J Public Health 2001;91:1435–1442.

40. Hassan I, Ismail KM, O’Brien S. PMS in the perimenopause. J Br Menopause Soc 2004;10:151–156.

41. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741–1744.

42. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988;11:556–561.

43. Gonen R, Sharf M, Lavie P. The association between midsleep waking episodes and hot flashes in post-menopausal women. J Psychosom Obstet Gynecol 1986;5:113–117.

44. Freedman RR, Roehrs TA. Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause 2006;13:576–583.

45. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: An hypothesis of flush mechanism. Clin Endocrinol (Oxf ) 1985;22:293–312.

46. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001;30:695–728; vii–viii.

47. Finkelstein JW, Roffwarg HP, Boyar RM, et al. Age-related change in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab 1972;35:665– 670.

48. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep 1998;21:553–566.

49. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392–398.

50. Landgren BM, Collins A, Csemiczky G, et al. Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause. J Clin Endocrinol Metab 2004;89:2763–2769.

51. Burger H, Teede H. Endocrine changes during the perimenopause. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:67–76.

52. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987;65:1231–1237.

53. Metcalf MG, Donald RA, Livesey JH. Pituitary-ovarian function in normal women during the menopausal transition.

Clin Endocrinol (Oxf ) 1981;14:245–255.

54. Robertson DM, Burger HG. Reproductive hormones: Ageing and the perimenopause. Acta Obstet Gynecol Scand 2002;81:612–616.

55. Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. Maturitas 1988;10:35–43.

56. Santoro N, Chervenak JL. The menopause transition. Endocrinol Metab Clin North Am 2004;33:627–636.

57. Burger HG. Diagnostic role of follicle-stimulating hormone (FSH) measurements during the menopausal transition: An analysis of FSH, oestradiol and inhibin. Eur J Endocrinol 1994;130:38–42.

58. Rannevik G, Carlstrom K, Jeppsson S, et al. A prospective long-term study in women from pre-menopause to postmenopause: Changing profiles of gonadotrophins, oestrogens and androgens. Maturitas 1986;8:297–307.

59. Longcope C, Franz C, Morello C, et al. Steroid and gonadotropin levels in women during the peri-menopausal years. Maturitas 1986;8:189–196.

60. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 1999;84:4025–4030.

61. Prior JC. Perimenopause: The complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397–428.

62. Miro F, Parker SW, Aspinall LJ, et al. Origins and consequences of the elongation of the human menstrual cycle during the menopausal transition: The FREEDOM Study. J Clin Endocrinol Metab 2004;89:4910–4915. 860 VAN DIE ET AL.

63. Weiss G, Skurnick JH, Goldsmith LT, et al. Menopause and hypothalamic-pituitary sensitivity to estrogen. JAMA 2004;292:2991–2996.

64. Yonkers KA, O’Brien PM, Eriksson E. Premenstrual syndrome. Lancet 2008;371:1200–1210.

65. Genazzani AR, Salvestroni C, Spinetti A, et al. Estrogens and neurotransmitters. In: Studd JWW, ed. The Management of the Menopause: Annual Review 1998. Carnforth, Lancs, UK: The Parthenon Publishing Group Limited, 1998: 169–175.

66. Sherwin BB. Hormones, mood, and cognitive functioning in postmenopausal women. Obstet Gynecol 1996;87(2 Suppl): 20S–26S.

67. Maggi A, Perez J. Role of female gonadal hormones in the CNS: Clinical and experimental aspects. Life Sci 1985;37: 893–906.

68. Da Sliva I, Naftolin F. Clinical effects of sex steroids on the brain. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 3rd ed. Burlington, MA: Academic Press, 2007:199–215.

69. Nair NP, Hariharasubramanian N, Pilapil C, et al. Plasma melatonin: An index of brain aging in humans? Biol Psychiatry 1986;21:141–150.

70. Haimov I, Laudon M, Zisapel N, et al. Sleep disorders and melatonin rhythms in elderly people. BMJ 1994;309:167.

71. Vakkuri O, Kivela A, Leppaluoto J, et al. Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol 1996;135:188–192.

72. Zimmerman R, Olcese J. Melatonin. In: Lobo R, ed. Treatment of the Postmenopausal Woman. Burlington, MA: Academic Press, 2007.

73. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:453–464.

74. Bruck K, Zeisberger E. Adaptive changes in thermoregulation and their neuropharmacological basis. Pharmacol Ther 1987;35:163–215.

75. Biegon A, Reches A, Snyder L, McEwen BS. Serotonergic and noradrenergic receptors in the rat brain: Modulation by chronic exposure to ovarian hormones. Life Sci 1983;32: 2015–2021.

76. Tuchman E. Exploring the prevalence of menopause symptoms in midlife women in methadone maintenance treatment. Soc Work Health Care 2007;45:43–62.

77. Simpkins JW, Katovich MJ, Song IC. Similarities between morphine withdrawal in the rat and the menopausal hot flush. Life Sci 1983;32:1957–1966.

78. Barros RC, Branco LG, Carnio EC. Evidence for thermoregulation by dopamine D1 and D2 receptors in the anteroventral preoptic region during normoxia and hypoxia. Brain Res 2004;1030:165–171.

79. Cagnacci A, Melis GB, Soldani R, et al. Regulation of body temperature in postmenopausal women: Interactions between bromocriptine and the endogenous opioid system. Life Sci 1989;44:1395–1402.

80. Zichella L, Falaschi P, Fioretti P, et al. Effects of different dopamine agonists and antagonists on post-menopausal hot flushes. Maturitas 1986;8:229–237.

81. Blum I, Vered Y, Lifshitz A, et al. The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women. Isr J Med Sci 1996;32: 1158–1162.

82. Gonzales GF, Carrillo C. Blood serotonin levels in postmenopausal women: Effects of age and serum oestradiol levels. Maturitas 1993;17:23–29.

83. Fink G, Sumner BE. Oestrogen and mental state. Nature 1996;383:306.

84. Dennerstein L, Lehert P, Guthrie JR, Burger HG. Modeling women’s health during the menopausal transition: A longitudinal analysis. Menopause 2007;14:53–62.

85. Ballinger CB, Browning MC, Smith AH. Hormone profiles and psychological symptoms in peri-menopausal women. Maturitas 1987;9:235–251.

86. Chakravarti S, Collins WP, Newton JR, et al. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977;84:769–775.

87. Soares CN, Cohen LS. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J 2001; 119:78–83.

88. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375–382.

89. Avis NE, Kaufert PA, Lock M, et al. The evolution of menopausal symptoms. Baillieres Clin Endocrinol Metab 1993;7:17–32.

90. Barden N, Merand Y, Rouleau D, et al. Changes in the betaendorphin content of discrete hypothalamic nuclei during the estrous cycle of the rat. Brain Res 1981;204:441–445.

91. Genazzani AR, Petraglia F, Mercuri N, et al. Effect of steroid hormones and antihormones on hypothalamic betaendorphin concentrations in intact and castrated female rats. J Endocrinol Invest 1990;13:91–96.

92. Wise PM, Rance N, Barraclough CA. Effects of estradiol and progesterone on catecholamine turnover rates in discrete hypothalamic regions in ovariectomized rats. Endocrinology 1981;108:2186–2193.

93. Jacobs PA, Hyland ME. An evaluation of the benefits of taking hormone replacement therapy with other prescription drugs. Maturitas 2003;46:273–281.

94. Paoletti AM, Floris S, Mannias M, et al. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab 2001;86:608–612.

95. Parry BL, Newton RP. Chronobiological basis of femalespecific mood disorders. Neuropsychopharmacology 2001; 25(S5):S102–S108.

96. Khan SA, Pace JE, Cox ML, et al. Climacteric symptoms in healthy middle-aged women. Br J Clin Pract 1994;48:240– 242.

97. Schmidt PJ, Nieman LK, Grover GN, et al. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. NEJM 1991;324:1174–1179.

98. Winer SA, Rapkin AJ. Premenstrual disorders: Prevalence, etiology and impact. J Reprod Med 2006;51(4 suppl):339– 347.

99. Richards M, Rubinow DR, Daly RC, Schmidt PJ. Premenstrual symptoms and perimenopausal depression. Am J Psychiatry 2006;163:133–137.

100. Hale G, Hughes C, Burger H, et al. Atypical oestradiol secretion and ovulation patterns caused by Luteal Out- Of-Phase (‘‘LOOP’’) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Menopause 2009;16:50–59.

101. Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med 2003;69:945–947.

102. Yen SSC, Jaffe RB. Prolactin in human reproduction. In: Yen SSC, Jaffe RB, Barbieri RL, ed. Reproductive VITEX AGNUS-CASTUS IN MENOPAUSE 861 Endocrinology. 4th ed. Philadelphia: WB Saunders, 1999: 276–277.

103. Halbreich U, Ben-David M, Assael M, Bornstein R. Serumprolactin in women with premenstrual syndrome. Lancet 1976;2:654–656.

104. Muhlenstedt D, Bohnet HG, Hanker JP, Schneider HP.Short luteal phase and prolactin. Int J Fertil 1978;23:213– 218.

105. Dietrich M, Hinnery B, Link M, et al. Latent hyperprolactinaemia as a cause of mastodynia and luteal function impairment. Vth International Congress Prolactin, 1988.

106. Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in late luteal phase dysphoric disorder. Int J Psychiatry Med 1990;20:279–284.

107. Chuong CJ, Hsi BP, Gibbons WE. Periovulatory betaendorphin levels in premenstrual syndrome. Obstet Gynecol 1994;83(5 Pt 1):755–760.

108. Facchinetti F, Moglia A, Bonuccelli U, et al. Pattern of plasma opioids in menstrually-related migraine and epilepsy. Funct Neurol 1986;1:415–419.

109. Facchinetti F, Martignoni E, Petraglia F, et al. Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. Fertil Steril 1987;47:570–573.

110. Diaz BL, Llaneza PC. Endocrine regulation of the course of menopause by oral melatonin: First case report. Menopause 2008;15:388–392.

111. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a doubleblind placebo-controlled study: Effects on menopause symptoms and bone markers. Maturitas 2003;44(suppl 1): S67–S77.

112. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105(5 Pt 1):1074–1083.

113. Nappi RE, Malavasi B, Brundu B, Facchinetti F. Efficacy of Cimicifuga racemosa on climacteric complaints: A randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005;20:30–35.

114. Geller SE, Studee L. Contemporary alternatives to plant estrogens for menopause. Maturitas 2006;55(suppl 1):S3– S13.

115. US Department of Health and Human Services FDA, Center for Drug Evaluation and Research (CDER). Guidance for industry: Labeling guidance for noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms— prescribing information for health care providers and patient labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research, CDER, 2004.

116. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen=progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.

117. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998;91:6–11.

118. Davis S, Briganti E, Chen RQ, et al. The effects of Chinese medicinal herbs on postmenopausal vasomotor symptoms of Australian women. Med J Austr 2001;174:68–71.

119. Knight DC, Howes JB, Eden J. The effect of PromensilTM, an isoflavone extract, on menopausal symptoms. Climacteric 1999;2:79–84.

120. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: Prospective, randomised, placebo controlled study. BMJ 2001;322:134–137.

121. Lauritzen CH, Reuter HD, Repges R, et al. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled, double-blind study versus pyridoxine. Phytomedicine 1997;4:183–189.

122. Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol 2003;18:191–195.

123. Propping D, Bohnert KJ, Peeters M, et al. Vitex agnus castus. The treatment of gynaecological syndromes. [in German]. Therapeutikon 1991;5:581–585.

124. Loch EG, Selle H, Boblitz N. Treatment of premenstrual syndrome with a phytopharmaceutical formulation containing Vitex agnus castus. J Womens Health Gend Based Med 2000;9:315–320.

125. Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150–153.

126. Linde K, Mulrow CD. St John’s wort for depression. Cochrane Database Sys Rev Abstracts 2000;2:CD000448.